A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL.

被引：0
|
作者：
Weiss, MA
Heffner, L
Lamanna, N
Kalaycio, M
Schiller, G
Coutre, S
Maslak, P
Jurcic, J
Panageas, K
Scheinberg, DA
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：564S / 564S
页数：1
相关论文
共 50 条
  • [21] Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen:: A randomized trial for adult patients with non IPI high-risk intermediate or high grade lymphomas (NHL).
    Milpied, N
    Deconninck, E
    Colombat, P
    Ifrah, N
    Delwail, V
    Berthou, C
    Gressin, R
    Lamy, T
    Jaubert, J
    Casassus, P
    Le Maignan, C
    Maisonneuve, H
    Ramée, JF
    Lemevel, A
    Jardel, H
    Moreau, P
    Harousseau, JL
    BLOOD, 1999, 94 (10) : 610A - 610A
  • [22] A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
    Betts, Robert F.
    Nucci, Marcio
    Talwar, Deepak
    Gareca, Marcelo
    Queiroz-Telles, Flavio
    Bedimo, Roger J.
    Herbrecht, Raoul
    Ruiz-Palacios, Guillermo
    Young, Jo-Anne H.
    Baddley, John W.
    Strohmaier, Kim M.
    Tucker, Kimberly A.
    Taylor, Arlene F.
    Kartsonis, Nicholas A.
    CLINICAL INFECTIOUS DISEASES, 2009, 48 (12) : 1676 - 1684
  • [23] Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O
    Sakura, Toru
    Hayakawa, Fumihiko
    Sugiura, Isamu
    Imai, Kiyotoshi
    Usui, Noriko
    Fujisawa, Shin
    Murayama, Tohru
    Yujiri, Toshiaki
    Kiyoi, Hitoshi
    Ohnishi, Kazunori
    Miyazaki, Yasushi
    Ohtake, Shigeki
    Kobayashi, Yukio
    Matsuo, Keitaro
    Naoe, Tomoki
    BLOOD, 2015, 126 (23)
  • [24] Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+Trial
    Roellig, Christoph
    Kramer, Michael
    Gabrecht, Maria
    Haenel, Mathias
    Herbst, Regina
    Kaiser, Ulrich
    Schmitz, Norbert
    Kullmer, Johannes
    Fetscher, Sebastian
    Link, Hartmut
    Mantovani-Loeffler, Luisa
    Kruempelmann, Ulrich
    Neuhaus, Thomas
    Heits, Frank
    Einsele, Hermann
    Ritter, Barbara
    Bornhaeuser, Martin
    Schetelig, Johannes
    Thiede, Christian
    Mohr, Brigitte
    Schaich, Markus
    Platzbecker, Uwe
    Schaefer-Eckart, Kerstin
    Kraemer, Alwin
    Berdel, Wolfgang E.
    Serve, Hubert
    Ehninger, Gerhard
    Schuler, Ulrich S.
    BLOOD, 2015, 126 (23)
  • [25] A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia (ALL).
    Weiss, M
    Maslak, P
    Megherian, L
    Scheinberg, D
    BLOOD, 1995, 86 (10) : 3131 - 3131
  • [26] A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: An Eastern Cooperative Oncology Group study (E3486)
    Wiernik, PH
    Cassileth, PA
    Leong, T
    Hoagland, HC
    Bennett, JM
    Paietta, E
    Oken, MM
    LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1515 - 1521
  • [27] Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia
    W. Hofmann
    G. Seipelt
    S. Langenhan
    R. Reutzel
    D. Schott
    O. Schoeffski
    H. Illiger
    F. Hartmann
    L. Balleisen
    A. Franke
    F. Fiedler
    C. Huber
    H. Rasche
    L. Bergmann
    A. Ganser
    C. Pott
    R. Pasold
    C. Rudolph
    O. Ottmann
    N. Gökbuget
    D. Hoelzer
    Annals of Hematology, 2002, 81 : 570 - 574
  • [28] Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia
    Hofmann, WK
    Seipelt, G
    Langenhan, S
    Reutzel, R
    Schott, D
    Schoeffski, O
    Illiger, HJ
    Hartmann, F
    Balleisen, L
    Franke, A
    Fiedler, F
    Huber, C
    Rasche, H
    Bergmann, L
    Ganser, A
    Pott, C
    Pasold, R
    Rudolph, C
    Ottmann, OG
    Gökbuget, N
    Hoelzer, D
    ANNALS OF HEMATOLOGY, 2002, 81 (10) : 570 - 574
  • [29] Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial Coall 08-09
    Escherich, Gabriele
    Stadt, Udo Zur
    Dilloo, Dagmar
    Faber, Joerg
    Feuchtinger, Tobias
    Imscheiler, Thomas
    Jorch, Norbert
    Pekrun, Arnulf
    Schmid, Irene
    Zimmermann, Martin
    Horstmann, Martin A.
    BLOOD, 2020, 136
  • [30] Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
    Ohtake, Shigeki
    Miyawaki, Shuichi
    Fujita, Hiroyuki
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Okumura, Hirokazu
    Miyamura, Koichi
    Nakaseko, Chiaki
    Miyazaki, Yasushi
    Fujieda, Atsushi
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Sakamaki, Hisashi
    Handa, Hiroshi
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2011, 117 (08) : 2358 - 2365
12345